Knowledge HQ

CAR-T cell therapy has emerged as a powerful weapon in the fight against specific B-cell malignancies. Its success has fueled significant research efforts to broaden its reach to encompass a wider range of hematologic and solid tumors.    Optimizing CAR-T cell therapy hinges on a deeper understanding of the intricate signaling pathways that govern these potent immune cells. This includes their ability to infiltrate tumors, evade antigen escape mechanisms, resist immunosuppression, and minimize potentially fatal toxicities. To achieve this, researchers require a comprehensive characterization of the signaling molecules involved, encompassing the extracellular, membrane-bound, and intracellular compartments. However, this endeavor is often hampered by limited and complex sample types.    The Wilson Wolf G-Rex platform offers a unique solution for large-scale expansion of CAR-T cells, enabling researchers to study these vital communication networks within larger, more robust cell populations. This facilitates a deeper understanding of CAR-T cell function and paves the way for the development of safer and more effective CAR-T therapies.    Unleash the Full Potential of CAR-T Cells: Learn More  Understanding these vital communication networks within CAR-T cells is critical to unlocking their full potential. Download our free App Note: Analytical Tools to Evaluate CAR-T Cell Signaling & Activation to explore the latest advancements in research methods for optimizing CAR-T cell therapy. 

TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.

Current iNK differentiation protocols typically utilize xenogenic feeder cells, which could be problematic for patient safety, or they lack robustness and are highly variable in differentiation efficiency. Using animal-free small molecules and recombinant proteins, Bio-Techne developed a feeder-free differentiation process to reliably generate iNKs at scale by optimizing for CD34+ hematopoietic stem cells (iHSC) prior to downstream NK differentiation.

Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process

Download the protocol to support a feeder-free process in G-Rex cell culture.

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.

Streamline your cell culture process with our new liquid frozen formulations of animal-free RUO and GMP IL-2, IL-7, and IL-15. These ready-to-use cytokines eliminate reconstitution errors while still providing the same potency and consistency as our lyophilized proteins. Simply thaw and add to your cell culture.

Utilization of G-Rex by introducing a new scalable depletion method: Coculturing target CAR T cells with an NK-92 cell line in G-Rex to purify their CAR T cells and promote CAR T cell expansion at the same time.

This scientific poster presented at CIMT 2023 investigates glioblastoma, a WHO grade IV glioma and the most common primary adult brain tumor, and the expression of elevated levels of HLA-E that block NK cells with expression of the inhibitory NKG2A receptor, aiming to establish a large-scale ex vivo expansion of functional NKG2C+ NK cells.  Doing so from peripheral blood employing bottom-gas permeable membrane bioreactors (G-Rex) and using a recently developed PC-3 feeder cell line genetically engineered with IL-2, membrane-bound IL-15, as well as a first generation single chain trimeric HLA-E molecule.

Join Anastasiya Smith, Snr. Director of R&D at Marker Therapeutics for a 15-minute pre-recorded webinar covering the first critical steps in successful automation through simplification with the G-Rex platform.

This is our proven process illustrating how ScaleReady works in a true partnership with your T and NK cell therapy program to enable the successful commercialization of your drug. This is a linear left-to-right, as well as a holistic view, of how at every stage, we look to simplify, streamline, and scale by offering expertise and support for your cell therapy program. Through our proven process, we deliver practical and viable solutions by providing the most simple, scalable, and versatile manufacturing products. Our process is proven, as our products are represented in approved CAR-T drugs around the globe.